Global reductions in healthcare funding are beginning to ripple across clinical trial systems, exposing vulnerabilities in supply chains, infrastructure, and site readiness—especially in emerging markets. As primary healthcare clinics (PHCs) serve both as frontline care providers and critical nodes in clinical research, their disruption creates compounding risks for investigational product distribution, cold chain integrity, and trial continuity.

This analysis explores how rebuilding PHC systems is essential not only for restoring public health services, but also for stabilizing clinical trial supply, improving global research resilience, and supporting the development of future therapies.